Glioblasztóma: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• TERT 3
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

35+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 401 115 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 78 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R42

  Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

  Crimson Biopharm Inc· Brookline, Egyesült Államok· 1 125 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · F31

  Co-engineering CAR T cells and CAR macrophages with synthetic cytokine signaling for glioblastoma immunotherapy

  Stanford University· Stanford, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NINDS · R21

  Regulation of Glioma Cell State Transition and Therapy Response by RNA Alternative Splicing

  Medical University of South Carolina· Charleston, Egyesült Államok· 188 750 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Svájc· EU contribution 292 119 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Hollandia· EU contribution 2 099 257 EUR· until 2032. máj.

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 1 484 173 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Németország· EU contribution 4 379 817 EUR· until 2030. dec.· 8 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 821 running projects, newest first. Listed amounts together: 403,5 M USD + 179,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Incyte Corporation· Frissítve: 2025. dec. 30.

  “Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

  NCT03718767· National Cancer Institute (NCI)· Forrás

• BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

  NCT03749187· University of California, San Francisco· Forrás

• Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

  NCT07448480· Blokhin's Russian Cancer Research Center· Forrás

• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Incyte Corporation· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• A Pan-Cancer Single-Cell Analysis of Intratumoral Copy-Number Diversity and Evolution.

  Cancer Discov, 2026. nov.

• Reconstructing the single-cell spatiotemporal dynamics of glioblastoma invasion.

  Nat Commun, 2026. nov.

• Advances in Single-Cell and Spatial Omics for Glioblastoma Precision Medicine.

  Curr Oncol Rep, 2026. okt.

• Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy.

  Front Immunol, 2026. okt.

• Beyond M1 M2: single-cell insights into how glioblastoma reshapes tumour-associated macrophages.

  Front Immunol, 2026. okt.

• Reduced Gene Module for Spatial Transcriptomics Recapitulates Single-Cell Molecular Classifications of Glioblastoma.

  Pathol Int, 2026. okt.

• In Cellulo Observation of De Novo-Synthesized Nucleotide by Spectral Tracing of Glutamine-Derived Nitrogen Metabolism (QN-STIM) in Cancer Cells.

  Anal Chem, 2026. szept.

• Multistage Genetic, Transcriptomic, and Single-Cell Evidence Prioritizes MAP1LC3A among Ferroptosis-Related Genes in Glioblastoma.

  J Vis Exp, 2026. szept.

• Integration of Single-Cell and Bulk RNA Sequencing Data to Identify Lactylation-Related Gene Signatures in Hepatic Ischemia-Reperfusion Injury Using Machine Learning Algorithms.

  Int J Mol Sci, 2026. szept.

• Single-cell Transcriptomic Characterization of DPP8 and DPP9 Expression Across Malignant Transcriptional States in Glioblastoma.

  J Pak Med Assoc, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.